Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 386 participants.
Also called NCT03115112
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 386 participants
- Sponsor
- Registry
-
NCT03115112
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Japan, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03115112. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-12 (actual); primary completion 2018-10-31 (actual). Results posted on 2021-06-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo for sitagliptin
- Intervention (Drug)
- Placebo for bexagliflozin
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct03115112- Content hash
e2e8b4711a8980704d27f2e6b28e7421a3ff7cfd5b6095279857954fd58b9490